News & Downloads

Noscendo expands proprietary diagnostic platform DISQVER® to include microbial resistances in partnership with University Hospital Bonn

Partnership plans molecular biological characterisation of up to 8000 clinically relevant isolates of pathogens resistant to multiple antibiotics using the latest sequencing technology. Press release Duisburg, 01/27/2020 – Noscendo GmbH and the University Hospital Bonn (UKB) today announced the successful signing of a cooperative agreement with the Institute for Hygiene and Public Health (IHPH) at the UKB, working towards expansion of the proprietary and CE-certified diagnostic platform DISQVER® in the field of microbial resistances. Through the partnership, Noscendo GmbH will…
Read More

ps
ps, on January 26, 2020

Noscendo erweitert proprietäre Diagnostikplattform DISQVER® um mikrobielle Resistenzen durch Kooperation mit dem Universitätsklinikum Bonn

Kooperation plant molekularbiologische Charakterisierung von bis zu 8.000 klinisch relevanten Isolaten von mehrfach antibiotikaresistenten Erregern mittels neuester Sequenziertechnologien. Pressemitteilung Duisburg, 27.01.2020 – Die Noscendo GmbH und das Universitätsklinikum Bonn (UKB) geben heute den Abschluss einer Kooperationsvereinbarung mit dem Institut für Hygiene und Öffentliche Gesundheit (IHPH) des UKB zur Erweiterung der proprietären und CE-markierten Diagnostikplattform DISQVER® im Bereich mikrobielle Resistenzen bekannt. Durch die Kooperation wird die Noscendo GmbH bis zu 8.000 antibiotikaresistente Erreger von über 35 Spezies mittels neuester Sequenziertechnologien vollumfänglich…
Read More

ps
ps, on January 26, 2020

Pressemitteilung – Noscendo erreicht die CE-Zertifizierung als wichtigen Meilenstein für seine proprietäre Diagnoseplattform DISQVER® und führt erfolgreiche Pilotversuche in acht Krankenhäusern der Maximalversorgung durch

Pressemitteilung Noscendo erreicht ersten Meilenstein mit CE-Markierung der proprietären Diagnostikplattform DISQVER® und führt erfolgreiche Pilotierung in 8 maximalversorgenden Kliniken durch Software ist Entwicklungsgrundlage automatisierter relevanzbasierter Erkennung von blutstromassoziierten Infektionen Duisburg, 10.09.2019 – Noscendo GmbH gibt heute den erfolgreichen Abschluss der Entwicklung der proprietärem Diagnostikplattform DISQVER® verbunden mit einer entsprechenden CE-Markierung als ersten wichtigen Meilenstein seit Firmenstart im Oktober 2018 bekannt. Noscendos Plattform kann ausgehend von Next-Generation-Sequencing (NGS) Bakterien, Pilze, DNA-Viren und Parasiten im Blutstrom der Patienten identifizieren und die Relevanz…
Read More

ps
ps, on September 9, 2019

Press Release – Noscendo reaches CE certification as key milestone for its proprietary diagnostic platform DISQVER® and conducts successful piloting in eight maximum care hospitals

Press Release Noscendo reaches CE certification as key milestone for its proprietary diagnostic platform DISQVER® and conducts successful piloting in eight maximum care hospitals Bioinformatic software is the basis for development in the automated relevance-based detection of blood-stream infections. Duisburg, 10.09.2019 – Noscendo GmbH today announced the successful completion of the development of its proprietary diagnostic platform DISQVER® combined with corresponding CE certification as the first key milestone since the seed financing in October 2018. Noscendo’s platform detects bacteria, fungi,…
Read More

ps
ps, on September 9, 2019

Press Release – Noscendo closes Financing Round for CE Certification and Market Entry Preparation of Platform Diagnostics for Bloodstream Associated Infections

Noscendo closes Financing Round for CE Certification and Market Entry Preparation of Platform Diagnostics for Bloodstream Associated Infections The diagnostic procedures developed by Noscendo help intensive care clinicians to identify the relevant pathogens in bloodstream associated infections. Munich-based family office Wieland Capital, HTGF and three business angels with in-depth knowledge of the diagnostics industry are jointly investing a seven-digit sum of Euros into Noscendo GmbH. These funds will enable Noscendo to receive approval for its medical device and prepare for…
Read More

ps
ps, on November 5, 2018

Philip Stevens, CEO of noscendo, honoree of “10 Innovators under 35” and “Innovator with most Social Impact 2018” awarded by MIT Technology Review

Our co-founder and CEO – Dr. Philip Stevens was awarded as “Innovator with most Social Impact 2018” by the renowned magazine “MIT Technology Review”. Technology review recognised the reach of Philip’s innovation and the work the team behind it is doing and honored this with the outstanding award as “Innovator with most Social Impact 2018”. Further, Philip is honoree of “10 under 35” in Germany. A list of Innovators, Entrepreneurs and Researchers with ground-breaking ideas in various disciplines. Philip was…
Read More

ps
ps, on July 4, 2018

NGS Diagnostics for the Detection of Mycoses in Patients with Septic Shock

An article recently published in the International Journal of Molecular Sciences shows how NGS technology can help diagnose critically ill patients suffering from Septic Shock. The article describes how NGS based detection of Mycoses helps clinicians to detect the causative fungal agent and how the overall diagnostic experience of the treating physician can be improved using the newest technologies. This second peer reviewed paper (first publication can be found here) shows the advantages of unbiased, agnostic NGS testing in the sepsis…
Read More

ps
ps, on September 1, 2017

noscendo wins EVC slot @ TechTour Data4Health Antwerp 17/18 May

In May 2017 noscendo participated at the Data 4 Health Event organized by TechTour in Antwerp. Welcoming 30 Startups from over 200 applicants from all around Europe the meeting was held to “bring together investors, entrepreneurs, corporations, government representatives and advisors from all over Europe, to look at innovative converging solutions using digital data”. During the meeting a lot of interesting discussion where going on. Especially after and during pitches of Start-Ups as well as reverse pitches. Especially during pitch sessions covering…
Read More

ps
ps, on June 20, 2017

Faster diagnosis of sepsis pathogens – MEDICA 2016

As the SIQ-Score technology was developed at the Fraunhofer IGB it was consequently shown at MEDICA 2016 in Duesseldorf. In preparation of the fair the online media news outlet Science daily published an article about the technology here on Nov 3, 2016  

rb
rb, on January 26, 2017

Circulating Cell-Free DNA Sequencing IDs Infectious Organisms in Pilot Study

In an article on July 8, 2016 the online media news outlet Genome Web picked up the peer-reviewed publication of Grumaz & Stevens et al. and interviewed Dr. Kai Sohn. As the head of the Functional Genomics group at the Fraunhofer IGB Kai discusses the challenges and opportunities of such new methods like the SIQ-score. The Genome Web article can be found here

ps
ps, on January 26, 2017